Rotavirus A serotype G1 (RV-G1)

Rotavirus serotype G1 is a major antigenic variant of Rotavirus A, primarily defined by the VP7 glycoprotein on its outer capsid [1]. It is the most common serotype associated with severe, dehydrating gastroenteritis in infants and young children globally [2]. As a primary therapeutic target, G1 is a core component of major vaccines such as Rotarix and RotaTeq, which are designed to induce protective mucosal immunity [3]. These vaccines work by stimulating the production of neutralizing antibodies and mucosal IgA that block the virus from infecting enterocytes in the small intestine [4]. Monitoring the prevalence and genetic evolution of the G1 serotype is essential for public health surveillance and for evaluating the long-term impact of global immunization programs [5]. The G1 serotype often pairs with the P[8] genotype, forming the G1P[8] strain that dominates many clinical settings [1]. Beyond vaccines, research into small-molecule antivirals often targets the replication machinery or entry mechanisms associated with this serotype [4]. Effective management of G1 infections relies on both preventative immunization and oral rehydration therapy to mitigate the effects of severe diarrhea [2].

Other names

Human rotavirus G1Rotavirus A G1P[8]VP7 glycoprotein G1G1 rotavirus

Vaccines containing G1 antigens stimulate the production of neutralizing antibodies (IgG and IgA) that target the VP7 protein, thereby blocking viral attachment and penetration into intestinal epithelial cells [3, 4].